Entity
  • Greywolf Therapeutics

    Created in 2017


  • Trend leader (A+)
    Existing signals make this entity one of the most dynamic startups
  • Social networks

    4,716 4,716
  • Activities

  • Technologies

  • Entity types

  • Location

    Milton Park Innovation Centre, 99 Park Dr, Milton, Abingdon OX14 4RR, UK

    Milton

    United Kingdom

  • Employees

    Scale: 11-50

    Estimated: 49

  • Engaged catalyst

    2
    0 0
  • Added in Motherbase

    2 years, 1 month ago
Description
  • Value proposition

    Solving immune dysfunction.

    Many cancers and other diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly.​

    We're progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system.​

    This approach marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases.

  • Greywolf Therapeutics

    Novel antigen modulation technology that controls T cells to guide the immune system

  • https://greywolftherapeutics.com/
  • Website is disabled or domain is for sale
Catalyst interactions
Catalyst TypeTweets Articles
UK Atomic Energy Authority
UK Atomic Energy Authority
Research, National and local authorities
UK Atomic Energy Authority
Research, National and local authorities
Other

29 Aug 2024


Oxford Science Enterprises
Oxford Science Enterprises
Startup accelerator & VC, Venture Capital and Private Equity Principals
Oxford Science Enterprises
Startup accelerator & VC, Venture Capital and Private Equity Principals
Other

12 Sep 2024


Social network dynamics
Similar entities
BETA
Loading...
Loading...